
Abbvie has gained sign-off for its rival treatment to challenge Gilead’s dominance of the growing market for new hepatitis C …

A payer is suing Gilead over the price of its hep-c drug Sovaldi in the US after spending $2.4 million …

Gilead Sciences’ new hepatitis C (HCV) tablet Harvoni has been approved across the European Union to treat the majority of …

The trajectory of Gilead’s new hep C pill Sovaldi has slowed but the drug is still on course to break …
The CHMP is recommending that Gilead’s new combination hepatitis C drug therapy Harvoni should be approved for use across the …

